(Q38042478)

27 August 2017

0 references

0 references

Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis. (English)

1 reference

27 August 2017

1 reference

4

Emmanuel Stip

1 reference

27 August 2017

Hoda Moteshafi

1

1 reference

27 August 2017

Simon Zhornitsky

series ordinal

2

1 reference

27 August 2017

Sarah Brunelle

series ordinal

3

1 reference

27 August 2017

publication date

1 October 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

35

1 reference

27 August 2017

issue

10

1 reference

27 August 2017

page(s)

819-836

1 reference

Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: a systematic review of the placebo-controlled monotherapy and add-on trials

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Onset of action of antipsychotics in the treatment of mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Olanzapine: a review of its use in the treatment of bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Olanzapine long-acting injection: a review of its use in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Weight effects associated with antipsychotics: a comprehensive database analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Metabolic syndrome with the atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Akathisia: an updated review focusing on second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Which comes first: atypical antipsychotic treatment or cardiometabolic risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Meta-analysis of MTHFR gene variants in schizophrenia, bipolar disorder and unipolar depressive disorder: evidence for a common genetic vulnerability?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Asenapine versus olanzapine in acute mania: a double-blind extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Maintenance of response following stabilization of mixed index episodes with olanzapine monotherapy in a randomized, double-blind, placebo-controlled study of bipolar 1 disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Weight gain, obesity, and metabolic indices following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Antipsychotic-induced weight gain and therapeutic response: a differential association.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Weight change with atypical antipsychotics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Antipsychotic drugs and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Severe hyperglycemia induced by olanzapine was improved with a recovery of insulin secretion after switching to risperidone and introducing insulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Impact of serotonin receptor 2A gene haplotypes on C-peptide levels in clozapine- and olanzapine-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Effect of antipsychotic medications on glucose and lipid levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Novel antipsychotics and severe hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: results from a 3-month prospective open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Pharmacogenomics of antipsychotics efficacy for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Evidence That Early Extrapyramidal Symptoms Predict Later Tardive Dyskinesia: A Prospective Analysis of 10,000 Patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261978

Dyslipidemia and atypical antipsychotic drugs.

21 January 2018

1 reference

12 December 2020

Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and association with tardive dyskinesia

1 reference

12 December 2020

Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study

1 reference

12 December 2020

Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo.

1 reference

12 December 2020

Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials.

1 reference

12 December 2020

Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states

1 reference

12 December 2020

An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine

1 reference

12 December 2020

Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group

1 reference

12 December 2020

Beyond pharmacotherapy: understanding the links between obesity and chronic mental illness

1 reference

12 December 2020

Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence

1 reference

12 December 2020

A systematic review of hypothalamic-pituitary-adrenal axis function in schizophrenia: implications for mortality

1 reference

12 December 2020

Bipolar depression: a new role for atypical antipsychotics?

1 reference

12 December 2020

A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study

1 reference

12 December 2020

Psychiatric diagnosis as an independent risk factor for metabolic disturbances: results from a comprehensive, naturalistic screening program.

1 reference

12 December 2020

Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial

1 reference

12 December 2020

Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia

1 reference

12 December 2020

The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics.

1 reference

12 December 2020

Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study.

1 reference

12 December 2020

A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia.

1 reference

12 December 2020

Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study

1 reference

12 December 2020

Antipsychotic-induced weight gain: a comprehensive research synthesis

1 reference

12 December 2020

Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges.

1 reference

12 December 2020

Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients

1 reference

12 December 2020

Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder

1 reference

12 December 2020

Common polygenic variation contributes to risk of schizophrenia and bipolar disorder

1 reference

12 December 2020

Higher frequency of neuroleptic-induced dystonia in mania than in schizophrenia

1 reference

12 December 2020

Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03261978

1 reference

Dimensions Publication ID

27 August 2017

1022757414

0 references

1 reference